NASDAQ · ECOR
electroCore, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ECOR: Nov 4, 2026
electroCore, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.26. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.26 | $-0.25 | $-0.27 | 2 |
| Dec 2026 | $-0.20 | $-0.19 | $-0.22 | 2 |
| Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Jun 2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Zacks · The Motley Fool- MarketBeat · Oct 28, 3:04 PM EDTelectroCore Targets 2027 EBITDA Profit as VA, Quell and CIPN Opportunities ExpandJoshua Lev, co-CEO, president and CFO of electroCore (NASDAQ:ECOR), said the commercial-stage bioelectronic health and wellness company is seeking to broaden its federal-market presence, expand product indications and reach adjusted EBITDA profitability in the second half of 2027
- RTTNews · Oct 28, 11:39 AM EDTElectroCore Files FDA Submission For Quell In Persistent Chemotherapy-Related Neuropathy; Stock Up(RTTNews) – electroCore, Inc. (ECOR) announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for its Quell wearable neuromodulation platform for the treatment of chronic chemotherapy-induced peripheral neuro
- Zacks · Sep 18, 9:09 AM EDTelectroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- MarketBeat · Aug 6, 9:03 PM EDTelectroCore Q2 Earnings Call HighlightselectroCore (NASDAQ:ECOR) reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue ou
- Zacks · Aug 6, 7:10 PM EDTelectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue EstimateselectroCore (ECOR) delivered earnings and revenue surprises of +19.51% and +0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 4, 5:15 PM EDTRigel Pharmaceuticals (RIGL) Q2 Earnings Miss EstimatesRigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · May 27, 3:54 AM EDTTop Biotech Gainers: CODX Soars On Ebola Assay Progress, NRXP Nears FDA Decision, NVAX On Watch(RTTNews) – Today's Top Gainers list includes CODX, which is advancing the development of its Ebola PCR Assay; NRXP, which has a couple of near-term regulatory catalysts to watch; ECOR, whose latest SEC filing reveals an insider transaction; and OTLK, which reported an encouragin
- MarketBeat · May 19, 3:02 AM EDTelectroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro ConferenceelectroCore (NASDAQ:ECOR) Interim President and CFO Joshua Lev said the bioelectronic technology company is focused on expanding its non-invasive vagus nerve stimulation platform across federal health care, commercial insurance channels and consumer wellness markets. Speaking at
- The Motley Fool · May 7, 10:15 AM EDTelectroCore (ECOR) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 6, 6:30 PM EDTelectroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue EstimateselectroCore (ECOR) delivered earnings and revenue surprises of -0.86% and +7.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 10, 9:57 AM EDTelectroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Apr 6, 9:11 AM EDTRelay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?Relay Therapeutics (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for electroCore, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.